Navigation Links
CytImmune Presents Positive CYT-6019 Data During the American,Society of Clinical Oncology Annual Meeting in Chicago

Chicago, IL -- CytImmune, a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies today presented a poster abstract at the 43rd American Society of Clinical Oncology (ASCO) Annual meeting. The poster, entitled "Preliminary Results of a Phase 1 Clinical Trial of CYT-6901," announced the preliminary data of a National Cancer Institute conducted and CytImmune Sciences sponsored Phase 1 trial of CYT-6091 (Aurimune), CytImmune's lead drug compound. The Phase 1 clinical trial was designed to investigate whether: (1) Aurimune will perform identically in humans as it did in preclinical studies and companion animals and (2) the fever side effect observed in preclinical studies can be easily managed and separated from hypotension - the dose limiting side effect of the active pharmaceutical ingredient.

"This is a tremendous opportunity for CytImmune," said Dr. Lawrence Tamarkin. "Presenting preliminary Phase 1 trial results to the leading body of international oncology experts helps pave the way for nanomedicines as the next generation of targeted cancer therapies and their use in improving the biodelivery of potent, but highly toxic therapeutics. We believe CYT-6091 has the potential to become a new, versatile therapeutic which may be used to treat a broad spectrum of solid tumors."

CYT-6091 (Aurimune), CytImmune's lead drug compound, is recombinant human tumor necrosis factor alpha (TNF) bound to the surface of 27 nanometer PEGylated colloidal gold nanoparticles. While TNF's tumor killing properties are well documented, its clinical use has been severely limited due to unacceptable toxicities.

To harness the potential of this anti-cancer agent, CytImmune's approach simultaneously binds PEG-Thiol and TNF to the surface of colloidal gold nanoparticles, whose design is to: (1) make them invisible to immune detection, thereby av oiding uptake by the liver and spleen and (2) target delivery of TNF directly to tumor sites.

At 27 nanometers in size, these nanoparticles are small enough to circulate safely through the body but too large to exit the blood stream except through the newly formed and leaky vasculature at solid tumors. TNF molecules on the surface of these gold nanoparticles act as tumor-targeting agents, binding to receptors at the site of disease and pulling nearly all TNF out of the circulation. By selectively accumulating TNF in and around solid tumors, Aurimune limits the biodistribution of TNF and prevents its uptake by healthy organs and tissues.

Preliminary data from the Phase 1 study indicates that CYT-6091 is seen in tumors, but not in healthy tissue, and that the mechanism of targeting solid tumors is independent of tumor type. To date the drug has had no effect on renal, liver or immune function and no unexpected serious adverse events have been reported. CYT-6091 induces a predictable and controllable febrile response, and has yet to induce hypotension, the dose limiting toxic effect of TNF.

"The next step is to safely and systemically administer doses of TNF at levels similar to the clinical experience with isolated limb perfusion where efficacy (i.e. tumor regression) has been observed in 85% of patients treated," said Tamarkin. "If successful, such an achievement represents a significant step forward in advancing cancer therapy."

In preclinical studies, CytImmune achieved safe and targeted delivery of TNF at levels necessary for biologic response - in some cases far exceeding established lethal doses for TNF alone.

The Phase 1 clinical trial for CYT-6091 (Aurimune) began in May 2006 at the NCI Center for Cancer Research, Bethesda, MD. To date, 15 patients have participated in the study. Patients included in the study thus far have been late-stage pancreatic, breast, colon, melanoma, sarcoma and lung cancer sufferers. Twelve addition al patients will be enrolled in this Phase I study which is due to be completed in December 2007.

Phase 1 preliminary trial data and the ASCO Poster Presentation can be found on the CytImmune website, www.cytimmune.com <http://www.cytimmune.com/> . All data has been released according to ASCO's Abstract Policy. The American Society of Clinical Oncology Annual Meeting is considered the premier educational and scientific event in the oncology community. In 2006, more than 29,000 attendees from around the world participated in the 42nd ASCO annual meeting in Atlanta, Georgia.

ABOUT CYTIMMUNE

CytImmune Sciences is a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies harnessing the unique properties of gold nanoparticles, known anti-cancer agents and biology of tumors. The platform technology allows for the targeted delivery of anti-caner therapies while avoiding update by healthy organs and tissues leading to improved efficacy, safety and patient outcomes. CytImmune hopes to build from this common core technology a family of therapeutics with faster development timelines, efficient regulatory approvals, new commercialization value, and greater patient benefits.


'"/>




Related medicine technology :

1. CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to be Presented on June 3, 2007
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... May 25, 2016 MedDay, a biotechnology ... that an oral presentation entitled "High doses of biotin in ... will be given by Professor Ayman Tourbah , Principal ... of the European Academy of Neurology (EAN) in ... disorders 3" will take place on Sunday, 29 May 2016 ...
(Date:5/24/2016)... 24, 2016   ... primären Endpunkte und demonstriert Ebenbürtigkeit bei ... ‚ausgezeichneter plus guter , ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) ... positive Daten von der MORA-Studie der Phase III ...
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a hot ... suggests that Americans prefer their dogs straight off the grill. Of the 90 percent ... favorite way to cook a hot dog, far outpacing other cooking methods such as ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... ... MadgeTech will be showcasing its line of data logging products , ... MadgeTech headquarters. With products sold in more than 100 countries around the world, MadgeTech ... , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data loggers around ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the ... Insurance is sharing tips to make sure your family and vehicle are ready ... Safety Council, there may be 439 deaths and an additional 50,500 serious injuries from ...
(Date:5/26/2016)... Rafael, CA (PRWEB) , ... May 26, 2016 ... ... will be offering campers a multitude of activities from daily practices, arts & ... self-confidence. , Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in ...
Breaking Medicine News(10 mins):